

# Mitochondrial Antibody Testing

Table of Content
<a href="#">Purpose</a>
<a href="#">Description &amp; Definitions</a>
<a href="#">Criteria</a>
<a href="#">Coding</a>
<a href="#">Document History</a>
<a href="#">References</a>
<a href="#">Special Notes</a>
<a href="#">Keywords</a>

<u>Effective Date</u>	10/2022
<u>Next Review Date</u>	10/15/2024
<u>Coverage Policy</u>	Medical 180
<u>Version</u>	5

**Member-specific benefits take precedence over medical policy and benefits may vary across plans. Refer to the individual’s benefit plan for details\*.**

**Purpose:**

This policy addresses the medical necessity of Mitochondrial Antibody Testing.

**Description & Definitions:**

Mitochondrial antibody (eg, M2) testing for either celiac disease or primary biliary cholangitis (primary biliary cirrhosis).

**Criteria:**

Mitochondrial Antibody Testing is considered medically necessary with **1 or more of the following**:

- Primary Biliary Cholangitis

Mitochondrial Antibody Testing is considered **not medically necessary** for any indication, to include but not limited

- Celiac disease

**Coding:**

Medically necessary with criteria:

Coding	Description
86381	Mitochondrial antibody (eg, M2), each

Considered Not Medically Necessary:

Coding	Description
	None

U.S. Food and Drug Administration (FDA) - approved only products only.

**Document History:**

Medical 180

Revised Dates:

- 2023: March

Reviewed Dates:

- 2021: April

Effective Date:

- May 2020

**References:**

Specialty Association Guidelines; Government Regulations; Winifred S. Hayes, Inc; UpToDate; Literature Review; Specialty Advisors; National Coverage Determination (NCD); Local Coverage Determination (LCD).

(2023). Retrieved Sep 26, 2023, from Hayes, Inc:

<https://evidence.hayesinc.com/search?q=%257B%2522text%2522:%2522mitochondrial%2520antibody%2522,%2522title%2522:null,%2522termsource%2522:%2522searchbar%2522,%2522page%2522:%257B%2522page%2522:0,%2522size%2522:50%257D,%2522type%2522:%2522all%2522,%2522sou>

(2023). Retrieved Sep 27, 2023, from Centers for Medicare and Medicaid Services: [https://www.cms.gov/medicare-coverage-database/search-](https://www.cms.gov/medicare-coverage-database/search-results.aspx?keyword=Mitochondrial%20antibody&keywordType=starts&areald=s53&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance)

[results.aspx?keyword=Mitochondrial%20antibody&keywordType=starts&areald=s53&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance](https://www.cms.gov/medicare-coverage-database/search-results.aspx?keyword=Mitochondrial%20antibody&keywordType=starts&areald=s53&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance)

(2023). Retrieved Sep 27, 2023, from Carelon Medical Benefits Management:

[https://guidelines.carelonmedicalbenefitsmanagement.com/?s=Mitochondrial+antibody&et\\_pb\\_searchform\\_submit=et\\_search\\_process&et\\_pb\\_search\\_cat=11%2C1%2C96&et\\_pb\\_include\\_posts=yes](https://guidelines.carelonmedicalbenefitsmanagement.com/?s=Mitochondrial+antibody&et_pb_searchform_submit=et_search_process&et_pb_search_cat=11%2C1%2C96&et_pb_include_posts=yes)

(2023, Jun 27). Retrieved Sep 27, 2023, from MCG: <https://careweb.careguidelines.com/ed27/index.html>

(2023). Retrieved Sep 28, 2023, from Department of Medical Assistance Services:

<https://vamedicaid.dmas.virginia.gov/manuals/provider-manuals-library#gsc.tab=0&gsc.q=mitochondrial%20antibody&gsc.sort=>

Mitochondrial Antibodies (M2), Serum. (2023). Retrieved Sep 28, 2023, from Mayo Clinic Laboratories:

<https://logan.testcatalog.org/show/MA>

Poupon, R. (2023, Mar 15). Clinical manifestations, diagnosis, and prognosis of primary biliary cholangitis. Retrieved Sep 26, 2023, from UpToDate: [https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-prognosis-of-primary-biliary-cholangitis?search=mitochondrial%20antibody&source=search\\_result&selectedTitle=3~150&usage\\_type=default&display\\_rank=3#](https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-prognosis-of-primary-biliary-cholangitis?search=mitochondrial%20antibody&source=search_result&selectedTitle=3~150&usage_type=default&display_rank=3#)

(2023). Retrieved Sep 28, 2023, from Google, Inc:

[https://www.google.com/search?q=Professional+recommendations+for+Mitochondrial+Antibody+Testing&safe=strict&scas\\_esv=569153003&sxsrf=AM9HkKnGmpLOu1pGQuxMvC9WTBsEajdA6A%3A1695921152328&ei=ALQVZZ7GE-6o5NoP1PKFoAk&ved=0ahUKEwixufO5s2BAxVuFFkFHVR5AZQQ4dUDCBA&](https://www.google.com/search?q=Professional+recommendations+for+Mitochondrial+Antibody+Testing&safe=strict&scas_esv=569153003&sxsrf=AM9HkKnGmpLOu1pGQuxMvC9WTBsEajdA6A%3A1695921152328&ei=ALQVZZ7GE-6o5NoP1PKFoAk&ved=0ahUKEwixufO5s2BAxVuFFkFHVR5AZQQ4dUDCBA&)

**Special Notes: \***

This medical policy expresses Sentara Health Plan's determination of medical necessity of services, and they are based upon a review of currently available clinical information. Medical policies are not a substitute for clinical judgment or for any prior authorization requirements of the health plan. These policies are not an explanation of benefits.

Medical policies can be highly technical and complex and are provided here for informational purposes. These medical policies are intended for use by health care professionals. The medical policies do not constitute medical advice or medical care. Treating health care professionals are solely responsible for diagnosis, treatment and medical advice. Sentara Health Plan members should discuss the information in the medical policies with their treating health care professionals. Medical technology is constantly evolving and these medical policies are subject to change without notice,

although Sentara Health Plan will notify providers as required in advance of changes that could have a negative impact on benefits.

**Keywords:**

SHP Mitochondrial Antibody Testing, SHP Medical 180, Celiac disease, Primary Biliary Cholangitis